RMR Wealth Builders Sells 157 Shares of Johnson & Johnson (NYSE:JNJ)

RMR Wealth Builders cut its position in Johnson & Johnson (NYSE:JNJ) by 3.1% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 4,967 shares of the company’s stock after selling 157 shares during the quarter. RMR Wealth Builders’ holdings in Johnson & Johnson were worth $718,000 at the end of the most recent reporting period.

Several other institutional investors have also added to or reduced their stakes in JNJ. Sugarloaf Wealth Management LLC lifted its position in shares of Johnson & Johnson by 2.0% during the 4th quarter. Sugarloaf Wealth Management LLC now owns 6,505 shares of the company’s stock valued at $941,000 after acquiring an additional 127 shares during the period. HBW Advisory Services LLC lifted its position in shares of Johnson & Johnson by 2.2% during the 4th quarter. HBW Advisory Services LLC now owns 6,534 shares of the company’s stock valued at $945,000 after acquiring an additional 141 shares during the period. Jacobs & Co. CA raised its holdings in shares of Johnson & Johnson by 0.3% during the 4th quarter. Jacobs & Co. CA now owns 56,569 shares of the company’s stock worth $8,181,000 after buying an additional 179 shares in the last quarter. Sage Capital Advisors llc raised its holdings in shares of Johnson & Johnson by 0.5% during the 4th quarter. Sage Capital Advisors llc now owns 43,731 shares of the company’s stock worth $6,324,000 after buying an additional 230 shares in the last quarter. Finally, Harbor Capital Advisors Inc. raised its holdings in shares of Johnson & Johnson by 2.5% during the 4th quarter. Harbor Capital Advisors Inc. now owns 49,879 shares of the company’s stock worth $7,214,000 after buying an additional 1,224 shares in the last quarter. 69.55% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

JNJ has been the subject of a number of research analyst reports. Cantor Fitzgerald reissued an “overweight” rating and set a $215.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 16th. Citigroup lowered their price target on Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating for the company in a report on Wednesday, December 11th. Guggenheim upped their target price on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Bank of America reaffirmed a “neutral” rating and issued a $166.00 target price on shares of Johnson & Johnson in a report on Tuesday, December 10th. Finally, Morgan Stanley upped their target price on Johnson & Johnson from $169.00 to $175.00 and gave the stock an “equal weight” rating in a report on Wednesday, October 16th. Seven analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $174.71.

Johnson & Johnson Stock Down 0.1 %

Shares of Johnson & Johnson stock opened at $142.07 on Friday. Johnson & Johnson has a one year low of $140.68 and a one year high of $168.85. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.03 and a quick ratio of 0.79. The stock’s 50-day moving average is $149.67 and its 200 day moving average is $155.99. The firm has a market cap of $342.05 billion, a price-to-earnings ratio of 20.56, a PEG ratio of 2.52 and a beta of 0.51.

Johnson & Johnson (NYSE:JNJ) last announced its earnings results on Tuesday, October 15th. The company reported $2.42 EPS for the quarter, beating the consensus estimate of $2.21 by $0.21. Johnson & Johnson had a return on equity of 35.45% and a net margin of 19.14%. The company had revenue of $22.47 billion for the quarter, compared to analyst estimates of $22.17 billion. During the same quarter in the prior year, the company earned $2.66 EPS. The firm’s revenue for the quarter was up 5.2% compared to the same quarter last year. Equities research analysts anticipate that Johnson & Johnson will post 9.94 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be given a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a dividend yield of 3.49%. Johnson & Johnson’s payout ratio is 71.78%.

Insider Activity at Johnson & Johnson

In other news, Director Mark A. Weinberger purchased 1,000 shares of the business’s stock in a transaction on Thursday, December 12th. The shares were acquired at an average price of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. The trade was a ? increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. 0.16% of the stock is owned by corporate insiders.

Johnson & Johnson Company Profile

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use.